ACOG Advises on Care for Transgender Patients ACOG Advises on Care for Transgender Patients
The committee opinion provides guidance for ob-gyns. on topics including inclusivity, routine screening, fertility and reproductive issues, hormone therapy, medication use, and surgery.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 2, 2021 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news
Molecular imaging determines effectiveness of novel metastatic breast cancer treatment
(Society of Nuclear Medicine and Molecular Imaging) Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called 18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2021 Category: Cancer & Oncology Source Type: news
Genomic test helps estimate risk of prostate cancer metastasis, death
(Johns Hopkins Medicine) A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 11, 2021 Category: Cancer & Oncology Source Type: news
Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposiu...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Imaging identifies breast cancer patients unlikely to benefit from hormone therapy
(Washington University School of Medicine) Hormone therapy can be very effective for so-called estrogen receptor-positive breast cancer. But it only works for a little more than half of women who receive the treatment. In a small study, researchers at Washington University School of Medicine in St. Louis found that women whose tumors did not respond to a one-day estrogen challenge did not benefit from hormone therapy. The findings could help doctors choose treatments most likely to help their patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 2, 2021 Category: International Medicine & Public Health Source Type: news
No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery No Need to Stop Estrogen in Transgender Women Before Gender-Affirming Surgery
Transgender women can safely maintain their estrogen hormone therapy during gender-affirming surgery without an increased risk of venous thromboembolism (VTE), according to a new study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 20, 2021 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news
Estrogen Therapy Need Not Stop for Gender - Affirming Surgery
Authors find that perioperative venous thromboembolism rarely occurs, regardless of suspension of hormone therapy prior to surgery (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 19, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Surgery, Journal, Source Type: news
Estrogen Therapy Need Not Stop for Gender-Affirming Surgery
TUESDAY, Jan. 19, 2021 -- For transgender and gender nonbinary (TGNB) patients undergoing primary vaginoplasty, perioperative venous thromboembolism (VTE) occurs rarely, regardless of whether hormone therapy is suspended prior to surgery, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2021 Category: Pharmaceuticals Source Type: news
What Is Hormone Therapy Used For
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 12, 2021 Category: General Medicine Source Type: news
Sexual dysfunction hits some women harder than others as they age
(The North American Menopause Society (NAMS)) Sexual dysfunction often accompanies the menopause transition. Yet, not all women experience it the same. A new study identified the determinants that affect a woman's risk of sexual dysfunction and sought to determine the effectiveness of hormone therapy in decreasing that risk and modifying sexual behavior. Study results are published online in Menopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - January 6, 2021 Category: International Medicine & Public Health Source Type: news
With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs.
The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer.
Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
With potential $4B Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs.
The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer.
Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 28, 2020 Category: American Health Authors: Ron Leuty Source Type: news
With potential $4 billion Pfizer deal, 'upside-down' Peninsula biotech on hunt for more drugs
Myovant Sciences Ltd. will use the financial muscle generated by a potential $4.2 billion deal with drug giant Pfizer Inc. to beef up its pipeline of cancer and women's health drugs.
The Pfizer compact, disclosed Monday, centers on Brisbane-based Myovant's potential blockbuster drug relugolix, which won Food and Drug Administration approval this month as the first oral hormone therapy for men with advanced prostate cancer.
Myovant's stock climbed as high as $30.90 per share M onday — a new 52-week… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 28, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
